History
Under the management philosophy of 'A company that respects and love human beings',
we are sincerely striving to fulfill corporate social responsibilities with the goal of a young and healthy life.
~ Goal
(2023 ~ 2025)
Sales target KRW 150 billion | |
Establishment of the 2nd factory | |
Establishment of additional product line-up | |
Challenge as an innovative pharmaceutical company | |
Increased export performance of TOX9 Injection (Botulinum toxin) | |
Establishment of the 2nd R&D center for finished products |
Current
Stabilization stage
Received the Consumer-Friendly Brand Grand Prize at the Korea Consumer Awards (For 5 consecutive years) |
|
Efforts to secure a variety of products by expanding new businesses
|
|
Increased sales (KRW 36.8 billion in 2016 KRW 89.5 billion in 2021) |
~ 2020
Growth stage
2017.05 | Construction of Botox manufacturing facility | |
---|---|---|
2016.12 | Expansion of company-affiliated research institute | |
2016.08 | Conducted M&A with Protox Inc. | |
2015.09 | Launched film-type erectile dysfunction treatment | |
2014.11 | Over-the-counter drug release - Himton Plus Soft Capsule (Comprehensive nutritional supplements) |
|
2014.10 | Acquisition of pharmaceutical wholesale license | |
2014.08 | Acquisition of medical device sales business | |
2013.05 | Launched functional cosmetics brand - Naience |
~ 2010
Market entry stage
2010.05 | Development and release of Isotretinoin 20mg for the first time in Korea - Nimegen Soft Capsule (Isotretinoin) |
|
---|---|---|
2008.12 | Promoting and introducing a voluntary compliance program | |
2007.11 | Awarded the 1 Million Dollar Tower on the 44th Trade Day | |
2000.01 | Changed company name to Medica Korea Co., Ltd. | |
1999.11 | Obtained food (manufacturing, processing) business license | |
1999.05 | Selected as a promising export small business (By Korea SMEs and Startups Agency) |
|
1999.03 | Selected as a promising small and medium-sized enterprises (By Korea Institute of Science and Technology) |
|
1997.01 | Establishment of a Central Research Institute for Businesses (Authorization No. 971014) |
~ 1995
~ 1976
Start-up stage
1993.12 | Development of third-generation platinum-based anticancer drugs | |
---|---|---|
1991.04 | Approval of KGMP implementation establishment | |
1988.11 | Completion of KGMP factory | |
1976.05 | Established Dong-il Pharmaceutical Co., Ltd. |